Related Experiment Video
Updated: Feb 20, 2026

Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
Adjunctive therapies in Kawasaki disease
1Kawasaki Disease Research Center, University of California San Diego, La Jolla, CA, USA.
Abstract:
Despite the administration of intravenous immunoglobulin (IVIg) at a dose of 2 g/kg, approximately 3-5% of children with acute Kawasaki disease (KD) may develop coronary artery aneurysms. IVIg-resistance, defined as recrudescence of fever more than 36 h after IVIg completion, is a risk factor for coronary artery abnormalities. Thus, several adjunctive therapies are being evaluated for use in IVIg-resistant KD patients and in patients with coronary artery abnormalities. In this review the role of some of these adjunctive therapies in treatment of children with KD is discussed.
More Related Videos
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Rheumatic Heart Disease III: Medical Management
Myocarditis III: Medical Management
Rheumatic Heart Disease IV: Nursing Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Mitral Stenosis III: Medical Management

